Expert Insights

Daniel Rosas, MD, discusses second-line treatment options for patients with advanced lung cancer who experience progression on chemoimmunotherapy.

Sarah Premji, MD, discusses whether emerging oral SERDs differ in HR-positive, HER2-negative breast cancer.

Edward Garon, MD, discusses the evolving role of biomarkers in enabling tumor-agnostic drug approvals across oncology.

Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.

Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naïve patients with chronic lymphocytic leukemia.

Adam Brufsky, MD, PhD, discusses the role of ctDNA and MRD in early-stage breast cancer.

Angeles Secord, MD, discusses the evolving role of HRD as a biomarker and the need for improved patient selection in advanced ovarian cancer.

Midun Mala, MD, assesses the use of adjuvant HAI pump therapy in patients with resected oligometastatic colorectal cancer with liver-only metastases.

Arnab Basu, MD, discusses emerging bladder preservation strategies in muscle-invasive bladder cancer in the setting of novel neoadjuvant therapies.